Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
ViiV Healthcare
Masking: Double-blind for BMS-6630368 treatment groups until the Week 24 Primary Endpoint analysis, then open label. The reference groups is all open-label.
Arms: 5 (4 BMS-663068 treatment groups and 1 reference group)
Intervention Model: Parallel (with unblinding after the Week 24 primary endpoint analysis)
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Plasma HIV-1 RNA ≥ 1000 copies/ml at Screening
Treatment experience with antiretroviral therapies (excluding integrase inhibitors)
Cluster of differentiation (CD)4+ T-cell count \> 50 cells/mm3
You may not be if
History (or evidence at Screening) of genotypic resistance to any component of the study regimen \[ Tenofovir Disoproxil Fumarate (TDF), Atazanavir (ATV), Raltegravir (RAL)\]
Certain laboratory and electrocardiogram (ECG) values
Clareo Health | HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
